These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 3418432)

  • 1. Drug utilization of vancomycin.
    Ioanilli AE; Sesin GP; O'Keefe E
    J Intraven Nurs; 1988; 11(4):239-44. PubMed ID: 3418432
    [No Abstract]   [Full Text] [Related]  

  • 2. Criteria for use of intravenous vancomycin for treatment of infections.
    Lin A; Flint N; Johnson M; Ostrosky J; Kirkwood C; Healy D
    Clin Pharm; 1990 Sep; 9(9):718-22. PubMed ID: 2225754
    [No Abstract]   [Full Text] [Related]  

  • 3. A retrospective drug utilization evaluation of vancomycin usage in paediatric patients.
    Hing WC; Bek SJ; Lin RT; Li SC
    J Clin Pharm Ther; 2004 Aug; 29(4):359-65. PubMed ID: 15271103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vancomycin for treatment of bacterial meningitis.
    Gump DW
    Rev Infect Dis; 1981; 3 suppl():S289-92. PubMed ID: 6896243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Giving vancomycin as a continuous infusion.
    Embleton ND; Berrington J
    Arch Dis Child Fetal Neonatal Ed; 2009 May; 94(3):F233-4. PubMed ID: 19383864
    [No Abstract]   [Full Text] [Related]  

  • 6. [Vancomycin and teicoplanin: differential aspects].
    Cobo J
    Enferm Infecc Microbiol Clin; 1995 Dec; 13(10):600-10. PubMed ID: 8808477
    [No Abstract]   [Full Text] [Related]  

  • 7. Adequacy of a vancomycin dosing regimen in patients receiving high-flux hemodialysis.
    Ariano RE; Fine A; Sitar DS; Rexrode S; Zelenitsky SA
    Am J Kidney Dis; 2005 Oct; 46(4):681-7. PubMed ID: 16183423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections.
    McKinnon PS; Sorensen SV; Liu LZ; Itani KM
    Ann Pharmacother; 2006 Jun; 40(6):1017-23. PubMed ID: 16720705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemiology of vancomycin-induced neutropenia in patients receiving home intravenous infusion therapy.
    Pai MP; Mercier RC; Koster SA
    Ann Pharmacother; 2006 Feb; 40(2):224-8. PubMed ID: 16434560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations.
    Thomson AH; Staatz CE; Tobin CM; Gall M; Lovering AM
    J Antimicrob Chemother; 2009 May; 63(5):1050-7. PubMed ID: 19299472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Penetration of vancomycin in cardiac and mediastinal tissues in humans].
    Martin C; Alaya M; Mallet MN; Viviand X; Ennabli K; Said R; de Micco P
    Pathol Biol (Paris); 1994 May; 42(5):520-4. PubMed ID: 7824325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vancomycin dosing and monitoring.
    Med Lett Drugs Ther; 2009 Apr; 51(1309):25. PubMed ID: 19343006
    [No Abstract]   [Full Text] [Related]  

  • 13. Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy.
    Ingram PR; Lye DC; Tambyah PA; Goh WP; Tam VH; Fisher DA
    J Antimicrob Chemother; 2008 Jul; 62(1):168-71. PubMed ID: 18334494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized prospective study comparing cost-effectiveness of teicoplanin and vancomycin as second-line empiric therapy for infection in neutropenic patients.
    Vázquez L; Encinas MP; Morín LS; Vilches P; Gutiérrez N; García-Sanz R; Caballero D; Hurlé AD
    Haematologica; 1999 Mar; 84(3):231-6. PubMed ID: 10189388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health economics assessment study of teicoplanin versus vancomycin in Gram-positive infections.
    Portolés A; Palau E; Puerro M; Vargas E; Picazo JJ
    Rev Esp Quimioter; 2006 Mar; 19(1):65-75. PubMed ID: 16688294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous-infusion vancomycin therapy for preterm neonates with suspected or documented Gram-positive infections: a new dosage schedule.
    Plan O; Cambonie G; Barbotte E; Meyer P; Devine C; Milesi C; Pidoux O; Badr M; Picaud JC
    Arch Dis Child Fetal Neonatal Ed; 2008 Nov; 93(6):F418-21. PubMed ID: 18450803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus.
    Sharpe JN; Shively EH; Polk HC
    Am J Surg; 2005 Apr; 189(4):425-8. PubMed ID: 15820454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes.
    Davis SL; McKinnon PS; Hall LM; Delgado G; Rose W; Wilson RF; Rybak MJ
    Pharmacotherapy; 2007 Dec; 27(12):1611-8. PubMed ID: 18041881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Invasive infections due to vancomycin-resistant enterococci in adult patients.
    Jean SS; Fang CT; Wang HK; Hsue PR; Chang SC; Luh KT
    J Microbiol Immunol Infect; 2001 Dec; 34(4):281-6. PubMed ID: 11825009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of glomerular filtration rate on the clearance of vancomycin administered by continuous infusion in burn patients.
    Dailly E; Le Floch R; Deslandes G; Pannier M; Jolliet P
    Int J Antimicrob Agents; 2008 Jun; 31(6):537-9. PubMed ID: 18462925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.